Real-World Use of Hypomethylating Agents (HMA)/Venetoclax Combinations in Patients with Myelodysplastic Neoplasms (MDS) in the Arabian Gulf Region

被引：0
|
作者：
Khadadah, Fatima [1 ]
Cherif, Honar [2 ]
El Omri, Halima [3 ]
Absi, Ahmed [4 ]
Merwass, Noor [5 ]
Abu Haleeqa, Mohamed I. [6 ]
Jaber, Waed [6 ]
Alhuraiji, Ahmad [7 ]
Pandita, Ramesh [1 ]
机构：
[1] Kuwait Canc control Ctr, Kuwait, Kuwait
[2] Natl Ctr Canc Care & Res, Hematol BMT, Doha, Qatar
[3] Hamad Univ, Ar Rayyan, Qatar
[4] Natl Guard Hlth Affairs, Princess Noorah Oncol Ctr, King Abdulaziz Med City Western Reg, Jeddah, Saudi Arabia
[5] Minist Natl Guard Hlth Affairs, Dept Adult Hematol & Stem Cell Transplantat, Princess Noorah Oncol Ctr, Jeddah, Saudi Arabia
[6] Sheikh Shakhbout Med Ctr, Abu Dhabi, U Arab Emirates
[7] Kuwait Canc Ctr, Shuwaikh, Kuwait
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181520
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Real-World Treatment Patterns and Transfusion Burden Among US Patients with Newly Diagnosed Myelodysplastic Syndromes (MDS)
    Mukherjee, Sudipto
    Slabaugh, S. Lane
    Copher, Ronda
    Johnson, Jonathan
    Buzinec, Paul
    Mearns, Elizabeth S.
    BLOOD, 2019, 134
  • [42] Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies
    Ucciero, Andrealuna
    Pagnoni, Federico
    Scotti, Lorenza
    Pisterna, Alessia
    Barone-Adesi, Francesco
    Gaidano, Gianluca
    Patriarca, Andrea
    Lunghi, Monia
    CANCERS, 2023, 15 (18)
  • [43] A Comparison of Acute Myeloid Leukemia (AML) Regimens: Hypomethylating Agents Combined with Ivosidenib or Venetoclax in Newly Diagnosed Patients with IDH1 Mutations: A Real-World Evidence Study
    Smith, B. Douglas
    Lachowiez, Curtis A.
    Ambinder, Alexander Joseph
    Binder, Gary
    Angiolillo, Anne
    Vestin, Assaf
    Paglia, Robert
    Potluri, Ravi
    Papademetriou, Eros
    LeBlanc, Thomas W.
    BLOOD, 2023, 142
  • [44] Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML- a Real-World Evidence Comparison By Treatment with Hypomethylating Agents plus Ivosidenib or Venetoclax
    Smith, Douglas
    Lachowiez, Curtis A.
    Ambinder, Alexander J.
    Binder, Gary
    Angiolillo, Anne
    Potluri, Ravi
    Papademetriou, Eros
    Leblanc, Thomas W.
    BLOOD, 2024, 144 : 2855 - 2856
  • [45] Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers
    Abaza, Yasmin
    Winer, Eric S.
    Murthy, Guru Subramanian Guru
    Shallis, Rory M.
    Matthews, Andrew H.
    Badar, Talha
    Geramita, Emily M.
    Kota, Vamsi K.
    Swaroop, Alok
    Doukas, Peter
    Bradshaw, Danielle
    Helenowski, Irene B.
    Liu, Yingzhe
    Zhang, Hui
    Im, Annie
    Litzow, Mark R.
    Perl, Alexander E.
    Atallah, Ehab
    Altman, Jessica K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (04) : 606 - 614
  • [46] Salvage Therapy with Hypomethylating Agents (HMA) and/or Lenalidomide (len) for Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapse Following Allogeneic Stem Cell Transplantation (allo-SCT)
    Singh, Meenu
    Dhakal, Binod
    Shrestha, Anuj
    Atallah, Ehab
    Carlson, Karen
    Pasquini, Marcelo C.
    Rein, Lisa
    Banerjee, Anjishnu
    Esselmann, Jean
    Ramirez, Sarah
    Zellner, Katie
    Essenmacher, Amber
    Hari, Parameswaran N.
    Michaelis, Laura C.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S357 - S357
  • [47] Association of Hypometilating Agents (HMA) plus Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine
    Latagliata, Roberto
    Cristiano, Gianluca
    Lama, Dorela
    Fenu, Susanna
    Rizzo, Lorenzo
    Cambo, Benedetta
    Zoletto, Simone
    Spirito, Francesca
    Cavalca, Fabrizio
    Cattaneo, Daniele
    Cenfra, Natalia
    De Luca, Giulia
    Vangone, Beatrice Esposito
    Di Veroli, Ambra
    Palmieri, Raffaele
    Annunziata, Mario
    Mulas, Olga
    Abruzzese, Elisabetta
    Molteni, Alfredo
    Piedimonte, Monica
    Carmosino, Ida
    Salutari, Prassede
    Biagi, Annalisa
    Bocchia, Monica
    Santopietro, Michelina
    Binotto, Gianni
    Iurlo, Alessandra
    Crugnola, Monica
    Riva, Marta
    Piccioni, Anna Lina
    Elli, Elena Maria
    Curti, Antonio
    Poloni, Antonella
    BLOOD, 2022, 140 : 6176 - 6178
  • [48] Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
    Zeidan, Amer M.
    Salimi, Tehseen
    Epstein, Robert S.
    FUTURE ONCOLOGY, 2021, 17 (36) : 5163 - 5175
  • [49] Real-World Impact of Luspatercept Versus Erythropoiesis-Stimulating Agents (ESAs) on the Healthcare Resource Utilization (HRU) of Patients With Myelodysplastic Syndromes (MDS) in the United States (US)
    Ball, Brian J.
    Song, Rui
    Zanardo, Enrico
    Huynh, Lynn
    Mohan, Manasi
    Pinaire, Megan
    Tang, Derek
    Yenikomshian, Mihran
    Swanson, Ashley
    Gavrilov, Svetlana
    Slaff, Samantha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S385 - S385
  • [50] Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.
    Zeidan, Amer M.
    Hu, Xin
    Long, Jessica B.
    Wang, Rong
    Huntington, Scott F.
    Podoltsev, Nikolai Alexandrovich
    Giri, Smith
    Stahl, Maximilian
    Gore, Steven
    Ma, Xiaomei
    Davidoff, Amy J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345